DERM logo

JOURNEY MEDICAL CORP

DERMNASDAQ
🏆 #3776 by market capEarnings Nov 11US Equity
$6.50▲ $0.06 (+0.93%)
Market closed · at close
🔔
Track DERM
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.9%
7d▼ 0.2%
14d▼ 11.0%
30d▼ 12.3%
ytd▼ 15.6%
1y▼ 8.6%
🏦Market Cap
$140M
Small Cap
📈Revenue Growth (YoY)
+20.9%
Healthy
📊Gross Margin
65.5%
High
💵FCF Margin
4.3%
Moderate
⚖️P/S Ratio
2.7x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$6.42 – $6.57
52-Week Range
$4.31 – $9.56
Volume
$2.01B
Avg Volume
$2.10B
Shares Outstanding
21.5M
Next Earnings
Nov 22, 2026

Fundamentals Snapshot

Annual Revenue
$62M
Last Q Revenue
$19M
P/E Ratio
—
P/S Ratio
2.7x
EPS (TTM)
$-0.23
Dividend Yield
—
Dilution (1yr)
+10.6%

Why Investors Own DERM

  • ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 61% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DERM logo

JOURNEY MEDICAL CORP

DERM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$62M▲ +10.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.3%▼ −5.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −40.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12M▼ −48.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
24.5M▲ +10.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$1M▲ +$4M YoY
StockOtter · stockotter.space

About JOURNEY MEDICAL CORP

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$8.54
▲ +31.4% Upside
High Target$9.81
Low Target$6.62
Based on 37 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

JOURNEY MEDICAL CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift DERM price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

JOURNEY MEDICAL CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.